# Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-for-combination-product-postmarketing-safety-reporting-immediately-in-effect-guidance-for-industry-and-food-and-drug-administration-staff/58ccec37-8610-4672-a40f-c7d571feb0f9

> FDA guidance document: Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff. Issue date: April 20, 2019. Get complete insights and analysis.

---

## Details

- Title: Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2019-04-20
- Last Changed: 2020-05-07
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2008-N-0424">FDA-2008-N-0424</a>

## Related Documents

- [Cross-Center Master Files: Where to Submit: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/cross-center-master-files-where-to-submit-draft-guidance-for-industry/6a5cada6-fa5a-48b8-a90f-54033cf59459)
- [Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/essential-drug-delivery-outputs-for-devices-intended-to-deliver-drugs-and-biological-products-draft-guidance-for-industry/4fd9f193-7d92-4a60-9cc8-fb2d65a0d90e)
- [Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff](https://www.globalkeysolutions.net/guidances/guidance-document/submissions-for-postapproval-modifications-to-a-combination-product-approved-under-a-bla-nda-or-pma-draft-guidance-for-industry-and-fda-staff/e6c53755-5cb5-49ce-9d67-07a008f66761)